Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  triple-negative breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 91 for your search:
Start Over
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, B-55/BIG 6-13, BIG 6-13, D081CC00006, NSABP B-55/BIG 6-13, NCT02032823
Platinum Based Chemotherapy or Capecitabine in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA1131, NCI-2014-01820, NCT02445391
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR003, NCI-2015-00128, NRG-BR1428, NCT02488967
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-119, NCI-2016-00327, 153082, 2015-001020-27, NCT02555657
Multitargeted Tyrosine Kinase Inhibitor PLX3397 and Eribulin Mesylate in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12751, NCI-2015-01321, 141658, CC#12751, NCT01596751
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
Cisplatin and Romidepsin in Treating Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT-2014-PS-BRST-CISRomiTNBC, NCI-2015-01524, RM-CL-BRST-PI-002783, STUDY00002219, NCT02393794
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Taselisib and Enzalutamide in Treating Patients with Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BRE 1374, NCI-2015-00795, BRE 1374, BRE 1374 / TBCRC 032, GO28972, TBCRC 032, NCT02457910
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7389-M001-218, NCI-2015-01436, KEYNOTE-150, NCT02513472
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
Durvalumab and Combination Chemotherapy in Treating Patients with Stage I-III Triple Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1409014537, NCI-2016-00070, ESR-14-10265, NCT02489448
Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3000-PN162-01-001, NCI-2016-00219, NCT02657889
A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-006, NCI-2016-00216, NCT02580448
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Locally Advanced or Inflammatory Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11174, NCI-2012-00025, 103352, 109696, 110312, 118191, NCT01525966
Paclitaxel and Cyclophosphamide with or without Trastuzumab before Surgery in Treating Patients with Previously Untreated Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 264-12, NCI-2012-01372, NCT01750073
Eribulin Mesylate in Treating Patients with HER2-Negative Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-077, NCI-2013-01115, NCT01827787
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Metastatic Triple-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9455, NCI-2013-01895, 2013C0069, OSU 13117, NCT01964924
Cisplatin or Paclitaxel before Surgery in Treating Patients with Triple Negative Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-383, NCI-2014-00955, 030, TBCRC 030, NCT01982448
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CDX011-04, NCI-2014-00373, NCT01997333
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BRE12-158, NCI-2015-00307, NCT02101385
Start Over